A. Azzedine

1.6k total citations · 1 hit paper
8 papers, 972 citations indexed

About

A. Azzedine is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, A. Azzedine has authored 8 papers receiving a total of 972 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 3 papers in Pulmonary and Respiratory Medicine and 2 papers in Surgery. Recurrent topics in A. Azzedine's work include Colorectal Cancer Treatments and Studies (3 papers), Pancreatic and Hepatic Oncology Research (2 papers) and Gastrointestinal Tumor Research and Treatment (2 papers). A. Azzedine is often cited by papers focused on Colorectal Cancer Treatments and Studies (3 papers), Pancreatic and Hepatic Oncology Research (2 papers) and Gastrointestinal Tumor Research and Treatment (2 papers). A. Azzedine collaborates with scholars based in France and Belgium. A. Azzedine's co-authors include Olivier Bouché, Laurent Bedenne, Pascal Hammel, Thomas Aparicio, Laurent Mineur, Bruno Chauffert, J Butel, J.-F. Bosset, Noël Stremsdoerfer and C. Mariette and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and Annals of Oncology.

In The Last Decade

A. Azzedine

8 papers receiving 957 citations

Hit Papers

Phase III trial comparing intensive induction chemoradiot... 2008 2026 2014 2020 2008 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study
    2008 501 citations Bruno Chauffert, F. Mornex et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
A. Azzedine France 6 733 422 228 214 213 8 972
Vishal Rana United States 11 412 0.6× 271 0.6× 249 1.1× 114 0.5× 151 0.7× 18 695
N. Androulakis Greece 20 1.1k 1.5× 681 1.6× 182 0.8× 290 1.4× 124 0.6× 46 1.3k
Chongqing Tan China 18 632 0.9× 541 1.3× 203 0.9× 104 0.5× 91 0.4× 65 978
Ralph Wong Canada 5 1.3k 1.7× 400 0.9× 220 1.0× 325 1.5× 169 0.8× 8 1.5k
D. Quietzsch Germany 14 886 1.2× 461 1.1× 210 0.9× 291 1.4× 191 0.9× 30 1.1k
P F Engstrom United States 8 650 0.9× 386 0.9× 239 1.0× 168 0.8× 228 1.1× 11 839
Rajarshi Roy United Kingdom 14 497 0.7× 687 1.6× 623 2.7× 146 0.7× 130 0.6× 30 1.2k
Do Hyoung Lim South Korea 15 725 1.0× 642 1.5× 365 1.6× 126 0.6× 75 0.4× 39 1.1k
B. Mirtsching United States 12 1.1k 1.6× 459 1.1× 131 0.6× 288 1.3× 136 0.6× 27 1.3k
B. Schüll Austria 14 639 0.9× 250 0.6× 128 0.6× 163 0.8× 102 0.5× 17 860

Countries citing papers authored by A. Azzedine

Since Specialization
Citations

This map shows the geographic impact of A. Azzedine's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Azzedine with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Azzedine more than expected).

Fields of papers citing papers by A. Azzedine

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Azzedine. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Azzedine. The network helps show where A. Azzedine may publish in the future.

Co-authorship network of co-authors of A. Azzedine

This figure shows the co-authorship network connecting the top 25 collaborators of A. Azzedine. A scholar is included among the top collaborators of A. Azzedine based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Azzedine. A. Azzedine is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
1.
Lacas, Benjamin, Olivier Bouché, Pierre-Luc Etienne, et al.. (2019). Quality of life and cost of strategies of two chemotherapy lines in metastatic colorectal cancer: results of the FFCD 2000-05 trial. Expert Review of Pharmacoeconomics & Outcomes Research. 19(5). 601–608. 2 indexed citations
2.
Touchefeu, Yann, Rosine Guimbaud, Christophe Louvet, et al.. (2018). Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: results from the randomized prospective phase III FFCD-0307 trial. Gastric Cancer. 22(3). 577–586. 5 indexed citations
3.
4.
5.
Ducreux, Michel, David Malka, Jean Mendiboure, et al.. (2011). Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000–05): an open-label, randomised, phase 3 trial. The Lancet Oncology. 12(11). 1032–1044. 114 indexed citations
6.
Chauffert, Bruno, F. Mornex, P. Rougier, et al.. (2008). Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study. Annals of Oncology. 19(9). 1592–1599. 501 indexed citations breakdown →
7.
Dadban, A., Borhane Slama, A. Azzedine, & G. Lepeu. (2008). Widespread granuloma annulare and Hodgkin's disease. Clinical and Experimental Dermatology. 33(4). 465–468. 18 indexed citations
8.
Façon, Thierry, Jean‐Luc Harousseau, F. Huguet, et al.. (2006). Superiority of melphalan-prednisone (MP) + thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma. Journal of Clinical Oncology. 24(18_suppl). 1–1. 148 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Vishal Rana Breakdown of academic impact, for papers by N. Androulakis Breakdown of academic impact, for papers by Chongqing Tan Breakdown of academic impact, for papers by Ralph Wong Breakdown of academic impact, for papers by D. Quietzsch Breakdown of academic impact, for papers by P F Engstrom Breakdown of academic impact, for papers by Rajarshi Roy Breakdown of academic impact, for papers by Do Hyoung Lim Breakdown of academic impact, for papers by B. Mirtsching Breakdown of academic impact, for papers by B. Schüll
Rankless by CCL
2026